These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 30963600)

  • 21. Genomic landscape and prognostic analysis of mantle cell lymphoma.
    Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
    Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How I manage mantle cell lymphoma: indolent versus aggressive disease.
    Wilson MR; Barrett A; Cheah CY; Eyre TA
    Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
    Klener P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.
    Radhakrishnan VS; Lokireddy P; Parihar M; Prakash PS; Menon H
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1590. PubMed ID: 34821081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Dreyling M
    Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on mantle cell lymphoma.
    Maddocks K
    Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
    Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
    Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.
    Girard J; Reneau J; Devata S; Wilcox RA; Kaminski MS; Mercer J; Carty S; Phillips TJ
    Onco Targets Ther; 2019; 12():8003-8014. PubMed ID: 31686856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.
    López C; Silkenstedt E; Dreyling M; Beà S
    Blood Adv; 2024 Jul; 8(14):3652-3664. PubMed ID: 38748869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
    Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):433-445. PubMed ID: 38641485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
    Yuan S; Zuo W; Liu T; Fu H
    Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
    [No Abstract]   [Full Text] [Related]  

  • 34. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
    Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
    Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.
    Bomben R; Ferrero S; D'Agaro T; Dal Bo M; Re A; Evangelista A; Carella AM; Zamò A; Vitolo U; Omedè P; Rusconi C; Arcaini L; Rigacci L; Luminari S; Piccin A; Liu D; Wiestner A; Gaidano G; Cortelazzo S; Ladetto M; Gattei V
    Haematologica; 2018 May; 103(5):849-856. PubMed ID: 29472356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
    Navarro Matilla B; García-Marco JA
    Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
    Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.